Quantification of reduced haloperidol and haloperidol by radioimmunoassay.
A radioimmunoassay for reduced haloperidol and haloperidol has been developed by using a simple derivatization-separation step prior to assay with an antibody cospecific for both compounds. The detection limit of the assay is less than 25 pg and shows no cross reactivity to other metabolites. The intraassay coefficient of variation for reduced haloperidol and haloperidol were 9.0 and 8.2% respectively and the interassay coefficients of variation were 9.0 and 10.6% respectively at 5-10 ng/ml. As many as 30 patient samples can be analyzed for both compounds in a single day.
D002853:Chromatography, Liquid; D003429:Cross Reactions; D006220:Haloperidol / Q000031:analogs & derivatives* / Q000097:blood* / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D011863:Radioimmunoassay / Q000379:methods*; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy
C040692:4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol; D006220:Haloperidol